BRPI0909183A2 - Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase - Google Patents

Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase

Info

Publication number
BRPI0909183A2
BRPI0909183A2 BRPI0909183-1A BRPI0909183A BRPI0909183A2 BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2 BR PI0909183 A BRPI0909183 A BR PI0909183A BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
treatment method
coa desaturase
condition treatment
Prior art date
Application number
BRPI0909183-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Bischoff
Kumar Sundaresan
Bala P Koteswara Rao
Bharathiraja Ainan
Hariharasubramanian Ayyamperumal
A R Girish
Srinivas Tatiparthy
Ganesh Prabhu
Hosahalli Subramanya
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of BRPI0909183A2 publication Critical patent/BRPI0909183A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0909183-1A 2008-03-20 2009-03-20 Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase BRPI0909183A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN575KO2008 2008-03-20
US4948008P 2008-05-01 2008-05-01
PCT/US2009/037835 WO2009117676A2 (en) 2008-03-20 2009-03-20 Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
BRPI0909183A2 true BRPI0909183A2 (pt) 2015-08-25

Family

ID=41089526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909183-1A BRPI0909183A2 (pt) 2008-03-20 2009-03-20 Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase

Country Status (14)

Country Link
US (1) US8129376B2 (enExample)
EP (1) EP2268143A4 (enExample)
JP (1) JP2011518774A (enExample)
KR (1) KR20100134680A (enExample)
CN (1) CN102036558A (enExample)
AU (1) AU2009225441B2 (enExample)
BR (1) BRPI0909183A2 (enExample)
CA (1) CA2719000A1 (enExample)
IL (1) IL208232A0 (enExample)
MX (1) MX2010010241A (enExample)
NZ (1) NZ588633A (enExample)
RU (1) RU2010142937A (enExample)
WO (1) WO2009117676A2 (enExample)
ZA (1) ZA201007252B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051244A1 (ja) 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
SG182662A1 (en) 2010-01-28 2012-08-30 Harvard College Compositions and methods for enhancing proteasome activity
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
NO2686520T3 (enExample) 2011-06-06 2018-03-17
FR3000491B1 (fr) * 2012-09-27 2015-08-28 Univ Lille Ii Droit & Sante Composes utilisables dans le traitement des infections mycobacteriennes
CN103772267A (zh) * 2012-10-24 2014-05-07 常州化学研究所 一种二苯胺制备咔唑的方法
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
SG11201607920RA (en) 2014-04-04 2016-10-28 X Rx Inc Substituted spirocyclic inhibitors of autotaxin
BR112016024473A2 (pt) * 2014-04-23 2018-01-23 X Rx Inc composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição
US20160047307A1 (en) * 2014-08-15 2016-02-18 General Electric Company Power train architectures with low-loss lubricant bearings and low-density materials
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
US11384081B2 (en) 2016-09-20 2022-07-12 Centre Leon Berard Benzoimidazole derivatives as anticancer agents
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020514293A (ja) 2017-01-06 2020-05-21 ユマニティ セラピューティクス,インコーポレーテッド 神経障害を治療する方法
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN107663184A (zh) * 2017-11-15 2018-02-06 上海皓伯化工科技有限公司 一种N‑Boc‑4‑羟基哌啶的合成方法
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
US10919885B2 (en) 2018-04-25 2021-02-16 Yumanity Therapeutics, Inc. Compounds and uses thereof
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
MX2021008903A (es) * 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CA3148310A1 (en) * 2019-09-13 2021-03-18 Jun Qi Kdm inhibitors and uses thereof
CN110845396B (zh) * 2019-11-07 2023-01-20 宿迁联盛科技股份有限公司 一种2,2,6,6-四甲基-4-哌啶胺类化合物的制备方法
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6659090A (en) 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
CA2398940C (en) 2000-02-24 2012-02-21 Xenon Genetics, Inc. Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
DE60134995D1 (de) 2000-09-26 2008-09-04 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
KR20050045927A (ko) 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
MX2007003319A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
WO2008157844A1 (en) * 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
JPWO2009119537A1 (ja) * 2008-03-26 2011-07-21 第一三共株式会社 ヒドロキシキノキサリンカルボキサミド誘導体

Also Published As

Publication number Publication date
ZA201007252B (en) 2011-12-28
US20090239810A1 (en) 2009-09-24
KR20100134680A (ko) 2010-12-23
EP2268143A4 (en) 2012-06-27
AU2009225441A1 (en) 2009-09-24
RU2010142937A (ru) 2012-04-27
MX2010010241A (es) 2010-12-06
NZ588633A (en) 2012-03-30
AU2009225441B2 (en) 2012-12-13
IL208232A0 (en) 2010-12-30
EP2268143A2 (en) 2011-01-05
US8129376B2 (en) 2012-03-06
CN102036558A (zh) 2011-04-27
WO2009117676A3 (en) 2010-01-07
WO2009117676A2 (en) 2009-09-24
JP2011518774A (ja) 2011-06-30
CA2719000A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
BRPI0909183A2 (pt) Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase
BRPI0817897A2 (pt) composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
BRPI0920284A2 (pt) composição e método
EP2315220A4 (en) REACTOR COMPONENT AND REACTOR
BRPI0919575A2 (pt) método, e, composição
BRPI0920498A2 (pt) método de tratamento de uma condição em um sujeito
BRPI0914770A2 (pt) anotação de conteúdo de página da web
BRPI0923011A2 (pt) método, e, produto de programa de computador
PT1976506T (pt) Extratos de plantas que contêm canabinoides como agentes neuroprotetores
EP2456310A4 (en) SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
BRPI0823277A2 (pt) Composição, e , método
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
BRPI0822472A2 (pt) Método, camundongo, e, composição
BRPI1015030A2 (pt) método de redução do conteúdo de compostos orgânicos voláteis solúveis em água presentes em um gás
FI20070935A0 (fi) Koostumus ja menetelmä puun käsittelemiseksi
FI20085564L (fi) Menetelmä puun suojaamiseksi
BRPI0823238A2 (pt) Composição, e, método
FR2942407B1 (fr) Procede de photomaquillage et composition de photomaquillage
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
BRPI0913511A2 (pt) método, arranjo e produto de programa de computador para determinar um estado de uma caixa de engrenagem"
EP2132251A4 (en) COMPOSITION AND METHOD
FI20060484L (fi) Lannoiterae ja menetelmä sen valmistamiseksi
DK2331310T3 (da) Imprægneringsanlæg og -fremgangsmåde
BRPI1015432A2 (pt) "composição e método para melhorar a saúde vascular"
NL2003138A1 (nl) Composition for preventing and treating fatty liver.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES IN 575/KOL/2008 DE 20/03/2008 E US 61/049,480 DE 01/05/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDEREM AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DAS REFERIDAS PRIORIDADES, QUE POSSUEM DEPOSITANTES DIFERENTES DO DEPOSITANTE DA FASE NACIONAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130064868 DE 24/07/2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO TEM FUNDAMENTACAO LEGAL.